$34.87
1.51% today
Nasdaq, Feb 28, 03:36 pm CET
ISIN
US79957L1008
Symbol
SMTI

Sanara MedTech Inc Stock price

$34.35
-2.34 6.38% 1M
+0.54 1.60% 6M
+1.15 3.46% YTD
-4.14 10.76% 1Y
+9.14 36.26% 3Y
+23.55 218.06% 5Y
+28.40 476.97% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-1.25 3.51%
ISIN
US79957L1008
Symbol
SMTI
Sector

Key metrics

Market capitalization $300.26m
Enterprise Value $315.57m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.04
P/S ratio (TTM) P/S ratio 3.85
P/B ratio (TTM) P/B ratio 7.55
Revenue growth (TTM) Revenue growth 24.66%
Revenue (TTM) Revenue $78.06m
EBIT (operating result TTM) EBIT $-8.45m
Free Cash Flow (TTM) Free Cash Flow $-1.99m
Cash position $16.28m
EPS (TTM) EPS $-0.99
P/E forward negative
P/S forward 3.48
EV/Sales forward 3.66
Short interest 5.78%
Show more

Is Sanara MedTech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Sanara MedTech Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Sanara MedTech Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Sanara MedTech Inc forecast:

Buy
100%

Financial data from Sanara MedTech Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
78 78
25% 25%
100%
- Direct Costs 12 12
2% 2%
15%
66 66
30% 30%
85%
- Selling and Administrative Expenses 66 66
29% 29%
85%
- Research and Development Expense 3.94 3.94
13% 13%
5%
-4.04 -4.04
17% 17%
-5%
- Depreciation and Amortization 4.41 4.41
22% 22%
6%
EBIT (Operating Income) EBIT -8.45 -8.45
0% 0%
-11%
Net Profit -8.36 -8.36
2% 2%
-11%

In millions USD.

Don't miss a Thing! We will send you all news about Sanara MedTech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sanara MedTech Inc Stock News

Positive
Seeking Alpha
29 days ago
Shares have risen nearly 15% since the company posted preliminary Q4 results, which showed revenue up by 45-48% year over year. While growth was boosted by one-off demand for its BIASURGE product, underlying growth was still strong at 37%. There remains a long runway for growth for its surgical products, with the potential for this to be augmented by other growth drivers, including inorganic op...
Neutral
GlobeNewsWire
about one month ago
SHANNON, Ireland, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Irish medical device company Biomimetic Innovations Limited, an affiliate of PBC Biomed, today announced the execution of an exclusive license and distribution agreement with Sanara MedTech Inc (“Sanara”) (Nasdaq:SMTI). In tandem, Sanara agreed to make a minority investment in cash for equity in BMI.
Neutral
GlobeNewsWire
about one month ago
OsStic ® and related technologies represent differentiated solutions that address an estimated 100,000+ procedures in the U.S. annually ( 1) ; arrangement leverages Sanara's existing call points and commercial infrastructure, and complements Sanara's existing surgical portfolio
More Sanara MedTech Inc News

Company Profile

Sanara MedTech, Inc.engages in the development, marketing, and distribution of biotechnology products to physicians, hospitals, and clinics. It offers CellerateRX Surgical Activated Collagen Adjuvant and HemaQuell Resorbable Bone Hemostat. The company was founded in 1982 and is headquartered in Fort Worth, TX.

Head office United States
CEO Ron Nixon
Employees 107
Founded 1982
Website www.sanaramedtech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today